Japan Chemical Research Epoetin Alfa Biosimilar Obtains Approval Recommendation
This article was originally published in PharmAsia News
Executive Summary
The First Committee on New Drugs at Japan's Ministry of Health, Labor and Welfare approved Nov. 27 Epoetin Alfa BS Injection JCR, a biosimilar product to Kyowa Hakko Kirin's Espo for chronic renal anemia